NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
Sumitomo Pharma America, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Utah
Bristol-Myers Squibb